CX3CL1 Promotes Cell Sensitivity to Ferroptosis and is Associated with the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2022 Nov 18

PMID 36397015

Authors

Qiming Gong

Zhiting Guo

Wenjuan Sun

Xiuri Du

Yan Jiang

Fahui Liu

Affiliations

Soon will be listed here.

Abstract

Background: An increasing number of studies have demonstrated that CX3CL1 is involved in the development of tumors and may thus be considered a new potential therapeutic target for them. However, the function of CX3CL1 in clear cell renal cell carcinoma (ccRCC) remains poorly defined.

Methods: The pan-cancer expression pattern and prognostic value of CX3CL1 were evaluated in this study. Moreover, the relationship of CX3CL1 expression with the tumor microenvironment, especially the tumor immune microenvironment, was analyzed. Our analyses employed public repository data. Additionally, we generated stable CX3CL1-overexpressing 786-O cells to determine the role of CX3CL1 in vitro via cell viability and transwell assays. A xenograft tumor model was used to determine the role of CX3CL1 in vivo. The association between CX3CL1 and ferroptosis sensitivity of tumor cells was assessed using Ferrostatin-1.

Results: Our findings indicated the involvement of CX3CL1 in the occurrence and development of ccRCC by acting as a tumor suppressor. We also found that ccRCC patients with high CX3CL1 expression showed better clinical outcomes than those with low CX3CL1 expression. The findings of our epigenetic study suggested that the expression of CX3CL1 in ccRCC is correlated with its DNA methylation level. Furthermore, the CX3CL1 expression level was closely related to the infiltration level of CD8 T cells into the tumor microenvironment (TME). CX3CL1 showed different predictive values in different immunotherapy cohorts. Finally, CX3CL1 overexpression inhibited tumor cell proliferation and metastasis and promoted tumor ferroptosis sensitivity in ccRCC.

Conclusions: This study revealed the role of CX3CL1 as a tumor suppressor in ccRCC. Our findings indicated that CX3CL1 plays a crucial role in regulating the ccRCC TME and is a potential predictor of immunotherapy outcomes in ccRCC. We also found that CX3CL1 can promote ferroptosis sensitivity in ccRCC cells.

Citing Articles

Ferroptosis-associated genes and compounds in renal cell carcinoma.

He C, Li Q, Wu W, Liu K, Li X, Zheng H Front Immunol. 2024; 15:1473203.

PMID: 39399506 PMC: 11466770. DOI: 10.3389/fimmu.2024.1473203.

Mechanisms of ferroptosis and targeted therapeutic approaches in urological malignancies.

Ma W, Jiang X, Jia R, Li Y Cell Death Discov. 2024; 10(1):432.

PMID: 39384767 PMC: 11464522. DOI: 10.1038/s41420-024-02195-w.

Identification of a senescence-related transcriptional signature to uncover molecular subtypes and key genes in hepatocellular carcinoma.

He X, Liu F, Gong Q PLoS One. 2024; 19(10):e0311696.

PMID: 39383169 PMC: 11463828. DOI: 10.1371/journal.pone.0311696.

Establishment and verification of a predictive model for bone metastasis in patients with non-small cell lung cancer based on peripheral blood CX3CL and CCL28.

Li S, Liu S, Fang S, Zhao F Am J Cancer Res. 2024; 14(6):3059-3067.

PMID: 39005684 PMC: 11236781. DOI: 10.62347/ONRF2499.

Targeting epigenetic and posttranslational modifications regulating ferroptosis for the treatment of diseases.

Wang Y, Hu J, Wu S, Fleishman J, Li Y, Xu Y Signal Transduct Target Ther. 2023; 8(1):449.

PMID: 38072908 PMC: 10711040. DOI: 10.1038/s41392-023-01720-0.

References

Yi X, Zheng X, Xu H, Li J, Zhang T, Ge P . IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer. Front Immunol. 2022; 13:898493. PMC: 9259832. DOI: 10.3389/fimmu.2022.898493. View

Chowdhury N, Drake C . Kidney Cancer: An Overview of Current Therapeutic Approaches. Urol Clin North Am. 2020; 47(4):419-431. DOI: 10.1016/j.ucl.2020.07.009. View

Jang S, Chapa-Dubocq X, Tyurina Y, St Croix C, Kapralov A, Tyurin V . Elucidating the contribution of mitochondrial glutathione to ferroptosis in cardiomyocytes. Redox Biol. 2021; 45:102021. PMC: 8187237. DOI: 10.1016/j.redox.2021.102021. View

Becht E, Giraldo N, Beuselinck B, Job S, Marisa L, Vano Y . Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). Oncoimmunology. 2015; 4(12):e1049804. PMC: 4635888. DOI: 10.1080/2162402X.2015.1049804. View

Liu J, Lichtenberg T, Hoadley K, Poisson L, Lazar A, Cherniack A . An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018; 173(2):400-416.e11. PMC: 6066282. DOI: 10.1016/j.cell.2018.02.052. View

Galon J, Bruni D . Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019; 18(3):197-218. DOI: 10.1038/s41573-018-0007-y. View

Kim M, Rooper L, Xie J, Kajdacsy-Balla A, Barbolina M . Fractalkine receptor CX(3)CR1 is expressed in epithelial ovarian carcinoma cells and required for motility and adhesion to peritoneal mesothelial cells. Mol Cancer Res. 2011; 10(1):11-24. PMC: 3262106. DOI: 10.1158/1541-7786.MCR-11-0256. View

Battaglia A, Chirillo R, Aversa I, Sacco A, Costanzo F, Biamonte F . Ferroptosis and Cancer: Mitochondria Meet the "Iron Maiden" Cell Death. Cells. 2020; 9(6). PMC: 7349567. DOI: 10.3390/cells9061505. View

Liu W, Liang Y, Chan Q, Jiang L, Dong J . CX3CL1 promotes lung cancer cell migration and invasion via the Src/focal adhesion kinase signaling pathway. Oncol Rep. 2019; 41(3):1911-1917. DOI: 10.3892/or.2019.6957. View

10.

Yang W, Zhang K, Li L, Xu Y, Ma K, Xie H . Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)-methyladenosine modification of MT-RNR1. J Exp Clin Cancer Res. 2021; 40(1):92. PMC: 7945252. DOI: 10.1186/s13046-021-01889-8. View

11.

Marchesi F, Piemonti L, Fedele G, Destro A, Roncalli M, Albarello L . The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res. 2008; 68(21):9060-9. DOI: 10.1158/0008-5472.CAN-08-1810. View

12.

Xu X, Wang Y, Chen J, Ma H, Shao Z, Chen H . High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2012; 16(8):1493-8. DOI: 10.1007/s11605-012-1921-7. View

13.

Satelli A, Rao U . Galectin-1 is silenced by promoter hypermethylation and its re-expression induces apoptosis in human colorectal cancer cells. Cancer Lett. 2010; 301(1):38-46. PMC: 3023883. DOI: 10.1016/j.canlet.2010.10.027. View

14.

Huang L, Ma B, Ma J, Wang F . Fractalkine/CX3CR1 axis modulated the development of pancreatic ductal adenocarcinoma via JAK/STAT signaling pathway. Biochem Biophys Res Commun. 2017; 493(4):1510-1517. DOI: 10.1016/j.bbrc.2017.10.006. View

15.

Gong Q, Jiang Y, Pan X, You Y . Fractalkine aggravates LPS-induced macrophage activation and acute kidney injury via Wnt/β-catenin signalling pathway. J Cell Mol Med. 2021; 25(14):6963-6975. PMC: 8278080. DOI: 10.1111/jcmm.16707. View

16.

Siddiqui I, Erreni M, van Brakel M, Debets R, Allavena P . Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. J Immunother Cancer. 2016; 4:21. PMC: 4836203. DOI: 10.1186/s40425-016-0125-1. View

17.

Sacco A, Battaglia A, Botta C, Aversa I, Mancuso S, Costanzo F . Iron Metabolism in the Tumor Microenvironment-Implications for Anti-Cancer Immune Response. Cells. 2021; 10(2). PMC: 7913036. DOI: 10.3390/cells10020303. View

18.

Jamieson W, Shimizu S, DAmbrosio J, Meucci O, Fatatis A . CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008; 68(6):1715-22. PMC: 2669735. DOI: 10.1158/0008-5472.CAN-07-1315. View

19.

Barroso-Sousa R, Keenan T, Li T, Tayob N, Trippa L, Pastorello R . Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. NPJ Breast Cancer. 2021; 7(1):110. PMC: 8387440. DOI: 10.1038/s41523-021-00287-9. View

20.

Hyakudomi M, Matsubara T, Hyakudomi R, Yamamoto T, Kinugasa S, Yamanoi A . Increased expression of fractalkine is correlated with a better prognosis and an increased number of both CD8+ T cells and natural killer cells in gastric adenocarcinoma. Ann Surg Oncol. 2008; 15(6):1775-82. DOI: 10.1245/s10434-008-9876-3. View